Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 499.6 INR -0.56% Market Closed
Market Cap: 1.2T INR

Operating Margin
Cipla Ltd

21.4%
Current
20%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
60.6B
/
Revenue
283.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Cipla Ltd
NSE:CIPLA
1.2T INR
21%
US
Eli Lilly and Co
NYSE:LLY
988.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
514B USD
27%
CH
Roche Holding AG
SIX:ROG
255.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP
24%
CH
Novartis AG
SIX:NOVN
207B CHF
33%
US
Merck & Co Inc
NYSE:MRK
242B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
146B USD
29%
No Stocks Found

Cipla Ltd
Glance View

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
1 248.51 INR
Overvaluation 17%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
21.4%
=
Operating Profit
60.6B
/
Revenue
283.5B
What is the Operating Margin of Cipla Ltd?

Based on Cipla Ltd's most recent financial statements, the company has Operating Margin of 21.4%.

Back to Top